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HIV-1 Nef is expressed in astrocytes, but a contribution to neuropathogenesis and the development of HIV-associated dementia (HAD)
remains uncertain. To determine the neuropathogenic actions of the HIV-1 Nef protein, the brain-derived (YU-2) and blood-derived (NL4-3)
Nef proteins were expressed in neural cells using an alphavirus vector, which resulted in astrocyte death (P b 0.001). Supernatants from Nef-
expressing astrocytes also caused neuronal death, suggesting the release of neurotoxic molecules by astrocytes. Analysis of pro-inflammatory
gene induction in astrocytes expressing Nef revealed increased IP-10 mRNA expression (4000-fold) that was Nef sequence dependent.
Recombinant IP-10 caused selective cell death in neurons (P b 0.001) but not astrocytes, and the cytotoxicity of supernatant from astrocytes
expressing Nef YU-2 was blocked by an antibody directed against the chemokine receptor CXCR3 (P b 0.001). SCID/NOD mice implanted
with a Nef YU-2-expressing vector displayed abnormal motor behavior (P b 0.05), neuroinflammation, and neuronal loss relative to controls.
Analysis of mRNA levels in brains from patients with HAD also revealed increased expression of IP-10 (P b 0.05), which was confirmed by
immunoreactivity detected principally in astrocytes. Phylogenetic and protein structure analyses of Nef sequences derived from HIV/AIDS
patients with and without HAD suggested viral evolution toward a neurotropic Nef protein. These results indicate that HIV-1 Nef contributes
to neuropathogenesis by directly causing astrocyte death together with indirect neuronal death through the cytotoxic actions of IP-10 on
neurons. Furthermore, Nef molecular diversity was evident in brain tissue among patients with neurological disease and which may influence
IP-10 production by astrocytes.
D 2004 Elsevier Inc. All rights reserved.
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Although 20% of untreated AIDS-defined patients will
develop HIV-associated dementia (HAD) (McArthur et
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neuroinflammation with accompanying neuronal and
astrocyte degeneration, resulting in HAD (Power and
Johnson, 2001). Both viral and aberrant host gene
expressions have been implicated in the pathogenesis of
HAD (Chen et al., 1997; Corder et al., 1998; Power et
al., 1998b; Quasney et al., 2001; van Rij et al., 1999).
Indeed, infection of the brain by HIV-1 and other
lentiviruses, and the subsequent production of viral
proteins in the brain are considered to play an important04) 302–318
G. van Marle et al. / Virology 329 (2004) 302–318 303role in the neuropathogenesis of lentivirus infections
(reviewed in Patrick et al., 2002).
The auxiliary HIV-1 protein Nef, which is expressed
early after infection, affects many cellular mechanisms
including cell survival (reviewed in Arora et al., 2002;
Doms and Trono, 2000; Fackler and Baur, 2002). For
both HIV and simian immunodeficiency virus (SIV),
deletion of the Nef open reading frame (ORF) is
associated with a delay in disease progression (Brambilla
et al., 1999; Kirchhoff et al., 1995; Rhodes et al., 2000),
although Nef is not an absolute requirement for systemic
immunosuppression (Jekle et al., 2002; Singh et al., 2002).
Polymorphisms in the Nef protein have been associated with
different functions and cellular distribution of the Nef
protein, which may affect both pathogenesis and cell fate
(Aldrovandi et al., 1998; Arora et al., 2002; Doms and
Trono, 2000). HIV-1 Nef transcripts and protein are
expressed in brain, and their presence is correlated with
neuroinflammation (Brack-Werner et al., 1992; Ranki et al.,
1995; Saito et al., 1994; Tornatore et al., 1994a). In pediatric
autopsied brains, Nef is the primary HIV gene expressed in
astrocytes (Saito et al., 1994; Tornatore et al., 1994a). HIV-1
infection of astrocytes in vitro is also typified by the
predominant expression of Nef encoding RNA transcripts
(Gorry et al., 1998; Tornatore et al., 1994b). The Nef protein
has variable effects on viral transcription and replication in
astrocytes (Ambrosini et al., 1999; Bencheikh et al., 1999;
Gorry et al., 1998), and the limited productive infection of
astrocytes is likely due to a defective function of the Rev
protein in astrocytes together with limited cell entry (Canki
et al., 2001; Ludwig et al., 1999).
Astrocytes represent the largest population of cells in the
central nervous system and are essential for its function
because of their neurotrophic and structural properties and
also their role as glutamate buffers (reviewed in Nedergaard
et al., 2003). Hence, infection of astrocytes by HIV-1 has
profound effects on viral neuropathogenesis, including
proximal neuronal function and survival. In a rodent model
of HIV-1 neuropathogenesis, Nef has been shown to
potentiate leukocyte infiltration in the brain, which could
facilitate infection of the CNS by HIV-1 (Koedel et al.,
1999). In addition, extracellular Nef is directly neurotoxic
(Trillo-Pazos et al., 2000), while complement expression by
immortalized astrocytes and neurons is upregulated by the
addition of recombinant Nef to culture media (Speth et al.,
2001, 2002). These observations are complicated by the
observation that Nef primarily resides inside the cell and is
not readily released, although it is present in virions (Arora
et al., 2002). Intracellular Nef could alter astrocyte function
by interfering with cell signaling pathways, which would
result in dysregulation of glutamate homeostasis (Wesse-
lingh and Thompson, 2001).
In the present study, our working hypothesis was that
intracellular HIV-1 Nef might perturb astrocyte function and
concurrently affect neuronal survival. Intracellular expres-
sion of Nef protein from a prototypic brain-derived HIV-1strain was cytotoxic to astrocytes in vitro and induced a
neuro-inflammatory response as well as neuronal injury in
vitro and in vivo. In addition, we showed that brain-derived
HIV-1 Nef could contribute to neurologic disease by
inducing IP-10 in astrocytes, which was toxic to neurons.
Analysis of the inflammatory response, including IP-10
expression, induced by different Nef proteins, derived from
the brains of HIV/AIDS patients, was variable, suggesting
that sequence diversity in the Nef protein contributes to
HIV-1 neuropathogenesis.Results
Expression of the HIV-1 Nef protein
To express the HIV-1 Nef proteins from prototypic
blood-derived (NL4-3) and brain-derived (YU-2) strains,
SINrep5-Nef YU-2 and SINrep5-Nef NL4-3 were con-
structed. Immunofluorescence and Western blot analysis of
BHK cells infected with different virus stocks showed
efficient expression of both the YU-2 and NL4-3 Nef
protein (Fig. 1A). In addition, morphological changes
including perikaryal shrinkage and process retraction were
observed in SINrep5-Nef-infected cells, corresponding to
the many reports of Nef’s effects on the cytoskeleton which
are not observed in SINrep5-enhanced green fluorescent
protein (EGFP)-infected BHK cells (Fackler et al., 1997,
1999; Kohleisen et al., 2001). As the nef gene is expressed
in astrocytes (Brack-Werner et al., 1992; Ranki et al., 1995;
Saito et al., 1994; Tornatore et al., 1994a), primary human
fetal astrocytes were also infected with SINrep5-Nef YU-2
or SINrep5-Nef NL4-3, showing efficient expression of the
Nef protein, again with perikaryal atrophy and process
retraction (Fig. 1B), while SINrep5-EGFP and mock-
infected astrocytes displayed no morphological abnormal-
ities. Of note, Nef immunoreactivity appeared as a doublet
on the Western blot (Fig. 1C), suggesting the presence of an
alternative translation start site for Nef YU-2 but not NL4-3,
which has previously been observed among different HIV-1
strains (Greenway et al., 1994; Kaminchik et al., 1991;
Zweig et al., 1990). The slower migration of both Nef-YU2
species was likely due to the 10 amino acid residue insertion
at position 23 relative to Nef NL4-3. Analysis of concen-
trated culture media derived from primary astrocytes
infected by SINrep5-Nef YU-2 and SINrep5-Nef NL4-3
by Western blot did not reveal a detectable release of the Nef
protein in the media (Fig. 1D) and similar results were
obtained for media of BHK cells infected with the
recombinant viruses (data not shown), suggesting that the
Nef protein is minimally secreted.
Cytotoxicity of HIV-1 Nef
To examine the cytotoxicity of the Nef protein and
explore the mechanism by which Nef contributes to HIV-1
Fig. 1. Expression of the Nef protein from HIV-1 strains NL4-3 and YU-2 by the SINrep5 expression vector. Nef protein immunofluorescence was detected in
both BHK-21 (A) and human primary astrocytes (B). Expression of the Nef protein in both cell types resulted in morphological changes including perikaryal
atrophy and process retraction that was more pronounced in astrocytes (B). Western blot analysis of cell lysates (C) and concentrated culture media (D) of Nef-
expressing astrocytes confirmed efficient expression of the Nef protein in astrocytes, but the Nef protein was not secreted into the culture media. The leftmost
lane in panel D is a positive control lysate of Nef YU-2-expressing cells.
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were infected with SINrep5-Nef viruses using equal
infectious inputs as determined via immunofluorescence
analysis for Nef-expressing cells. The cytotoxicity of
SINrep5-Nef YU-2 and -NL4-3 viruses was substantial for
astrocytic (U373) cells compared to controls at 24 and 48 h
postinfection (P b 0.01 and P b 0.001, respectively) (Fig.
2A). These studies showed that the cytotoxic effects of the
SINrep5-EGFP vector were minimal and comparable to
mock-infected cells (Fig. 2A). The percentage of cell death
after 24 or 48 h of infection revealed no significant
difference in cytotoxicity to neuronal (LAN-2) cells for
both SINrep5-Nef viruses compared with mock or SINrep5-
EGFP infection. Assessment of the cytotoxic effects of Nef
YU-2 and NL4-3 on human primary fetal astrocytes (Fig.
2B) corroborated our findings with the astrocytic cells
(U373), revealing increased astrocyte death 24 and 48 h
after infection with SINrep5-Nef. These results indicate that
intracellular expression of the HIV-1 Nef protein selectively
induced astrocyte death.Infection by HIV-1 results in the activation of astrocytes
and macrophages resulting in the release of soluble
molecules with neurotoxic actions (Gonzalez-Scarano and
Baltuch, 1999; Kaul et al., 2001). To determine if the Nef
protein is able to induce the release of soluble neurotoxins
from astrocytes and macrophages, human primary astro-
cytes and MDM were infected with SINrep5-Nef YU-2 or
SINrep5-Nef NL4-3 using SINrep5-EGFP- and mock-
infected cells as control. Neuronal cells were incubated for
24 and 48 h with the conditioned media derived from
infected primary astrocytes and MDM, and cell death was
subsequently evaluated. The conditioned media from the
human primary astrocytes (Fig. 2C) infected by SINrep5-
Nef YU-2 was highly neurotoxic after 48 h, which was not
observed for SINrep5-Nef NL4-3, SINrep5-EGFP, or mock-
infected astrocyte supernatants (P b 0.001), suggesting that
differences in the Nef sequence might influence the extent
of neuronal death. Conversely, incubation of neuronal cells
for 24 and 48 h with conditioned media from MDM infected
with either SINrep5-Nef YU-2 or SINrep5-Nef NL4-3
Fig. 2. Induction of cell death in astrocytic and neuronal cells by Nef. (A) Relative fold change (RFC) in cell death was significantly increased in astrocytic cells
(U373) infected with SINrep5-Nef YU-2 or -Nef NL4-3 compared to uninfected (mock) and SINrep5-EGFP-infected cells, while no increase in cell death was
observed in neuronal (LAN-2) cells. (B) Expression of Nef YU-2 and NL4-3 in human primary astrocytes also induced an increase in cell death, which was not
observed in controls. In addition, the neurotoxicity of conditioned media from primary human astrocytes (C) and MDM (D) infected for 24 h with SINrep5-Nef
YU-2, -Nef NL4-3, -EGFP, or uninfected (mock) was tested on LAN-2 cells, revealing that only the media of primary human astrocytes infected with SINrep5-
Nef YU-2 led to an increase in neuronal death after 48 h compared to media from SINrep5-Nef NL4-3, -EGFP, and uninfected astrocytes (mock), while cell
death was significantly increased in neuronal cells upon incubation with conditioned media of MDM for both SINrep5-Nef YU-2 and -Nef NL4-3 (*P b 0.05,
***P b 0.001, Dunn’s multiple comparison test). (Cell death mock-infected LAN-2, 24 h, 1.9 F 0.3%, 48 h, 2.2F 0.2%, cell death mock-infected U373, 24 h,
1.5 F 0.3%, 48 h, 2.4 F 0.2%, cell death mock-infected primary astrocytes, 24 h, 9.6 F 0.6%, 48 h, 10.8 F 0.8%, cell death media uninfected control MDM
24 h, 4.5 F 0.3%, 48 h, 5.2 F 0.29%, cell death media uninfected astrocytes 24 h, 3.9 F 0.47%, 48 h, 6.5 F 0.3%.)
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compared to incubation with conditioned media derived
from SINrep5-EGFP- and mock-infected MDMs (Fig. 2D).
Infection of MDM with both SINrep5-Nef viruses did not
cause an increase in cell death after 24 and 48 h (data not
shown). Thus, HIV-1 Nef was directly cytotoxic to
astrocytes while also indirectly influencing neuronal sur-
vival by the release of a neurotoxin.
Effects of HIV-1 Nef in vivo
Transgenic animal models expressing Nef protein in the
CNS develop neurological disease (Hanna et al., 1998,
2001), which prompted us to study the effects of the HIV-1
Nef protein expressed by SINrep5 expression in vivo. The
striatum of 3-week-old SCID/NOD mice was stereotacti-cally implanted with SINrep5-Nef YU-2, SINrep5-EGFP, or
conditioned media mock-transfected cells (CM) (six animals
per group). This brain region was selected because it is
highly vulnerable to the effects of HIV-1 infection (Power
and Johnson, 2001) and also permits neurobehavioral
analyses, which reflect neuronal injury (van Marle et al.,
2003; Zhang et al., 2003). To assess neuronal damage since
expression of the Nef YU-2 protein, amphetamine-induced
total rotational behavior of the mice was analyzed 3, 7, and
14 days after striatal implantation (Ungerstedt and Arbuth-
nott, 1970) (Fig. 3A). The total number of rotations of the
animals implanted with SINrep5-Nef YU-2 was signifi-
cantly lower (P b 0.05, Mann–Whitney U) at day 14, but
not days 3 and 7, compared to SINrep5-EGFP- and control-
implanted animals. The diminished levels of amphetamine-
induced rotary behavior were indicative of neuronal injury
Fig. 3. Neurobehavioral analyses after implantation of the striatum of SCID/NOD mice with SINrep-Nef YU-2, EGFP, or uninfected supernatant (A) revealed a
reduction of amphetamine-induced total rotational activity at day 14 in SINrep5-Nef YU-2-implanted animals suggesting neuronal damage (*P b 0.05, Dunn’s
multiple comparison test). Nef immunoreactivity was detected in neural cells in the SINrep5-Nef YU-2-implanted mice (C), which was absent in control
animals (B). Neuropathological findings in brain of SCID/NOD mice at day 14 following stereotactic implantation of uninfected supernatant (D, G, and J) or
implantation with SINrep5-EGFP (E, H, and K) and SINrep5-Nef YU-2 (C, F, and I) were assessed using expression of cell markers for inflammation and
activation of astrocytes (GFAP) (D, E, and F), microglia (Iba-1) (G, H, and I), and neuronal nuclei marker (NeuN) (J, K, and L) in striatal sections. Increased
astrogliosis (F) and microgliosis (I) with neuronal loss (L) was observed in animals implanted with SINrep5-Nef YU-2, which was not present in control
animals or animals implanted with SINrep5-EGFP.
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Immunofluorescence studies showed that Nef expression
was detectable near the implantation site unlike controls(Figs. 3B and C), indicating that Nef expression was
associated with neurobehavioral deficits. To determine if
this neurobehavioral deficit was correlated with neuro-
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revealed minimal activation of microglia and astrocytes,
respectively, surrounding the injection site in control
animals (Figs. 3D and G) and SINrep5-EGFP-implanted
animals (Figs. 3E and H). In contrast, the number of both
activated and hypertrophied astrocytes and microglia was
increased in all animals implanted with SINrep5-Nef YU-2
(Figs. 3F and I) compared to control animals in all sections
analyzed containing and adjacent to the injection site (four
sections per animal). Moreover, neuronal loss was also
observed at the site of injection in animals implanted with
SINrep5-Nef YU-2, indicated by loss of neuronal nuclear
protein (NeuN) immunoreactivity (Fig. 3L). Overall, these
results revealed that HIV-1 Nef induced in vivo neuro-
pathogenic effects upon implantation into the striatum of
mice, confirming our in vitro findings of Nef-mediated
neurotoxicity.
Induction of inflammatory molecules in astrocytes by HIV-1
Nef
The Nef protein has been shown to have pro-
inflammatory properties and enhance the recruitment of
leucocytes to the brain (Koedel et al., 1999). Because
stimulated astrocytes produce pro-inflammatory molecules,
which play an important role in the neuropathogenesis of
HIV-1, the effects of Nef on the expression of host
inflammatory genes was examined in terms of the mRNA
abundance of the chemotactic chemokines MCP-1 and IP-
10, because they are involved in recruitment of macro-
phages, the CNS especially, in HIV infection (Conant et
al., 1998; Sanders et al., 1998; Sui et al., 2003), as well as
the pro-inflammatory cytokine IL-1h in astrocytes infected
with SINrep5-Nef NL4-3, -Nef YU-2, -EGFP, or mock-
infected astrocytes (Fig. 4A). Infection of astrocytes with
SINrep5-Nef YU-2 resulted in a marked increase in IP-10
expression, while IP-10 mRNA was only minimally
detected in SINrep5-EGFP- or mock-infected astrocytes
and at low levels in SINrep5-Nef NL4-3 (Fig. 4A).
Similarly, SINrep5-Nef YU-2 infection was also associ-
ated with a significant increase of IL-1h expression (Fig.
4A). Conversely, both SINrep5-Nef NL4-3 and SINrep5-
Nef YU-2 induced a significant increase in MCP-1
expression (P b 0.05) (Fig. 4A). Immunofluorescent
analysis of infected human primary astrocytes confirmed
that IP-10 was detected in astrocytes infected with
SINrep5-Nef YU-2 but not in the mock- or SINrep5-
EGFP-infected cells (Fig. 4B). Analysis of the relative
expression levels of Nef protein using Western blot
analysis (Fig. 1C) suggests lower expression of Nef YU-
2 compared to Nef NL4-3 due either to differences in
viral vector replication or transcription (although a differ-
ence in immunoreactivity cannot be excluded). Nonethe-
less, these observations underscore the cytotoxic properties
of Nef YU-2, indicating that Nef YU-2 expressed even at
these lower levels is a more potent inducer of astrocytedeath, indirect neuronal death, and pro-inflammatory gene
expression.
IP-10-mediated neurotoxicity
The culture media derived from BHK cells and
astrocytes infected by SINrep5-Nef YU-2 by Western blot
did not reveal a detectable release of the Nef protein in the
media (Fig. 1D), suggesting that the Nef protein itself is
not directly responsible for the observed neurotoxicity of
media from SINrep5-Nef YU-2 infected astrocytes (Fig.
3D). Because we observed a substantial increase in IP-10
after Nef expression in astrocytes and IP-10 has been
implicated in neuronal dysfunction in Alzheimer’s disease
through its interaction with its cognate receptor CXCR3
(Xia et al., 2000), we explored the possibility of a
neurotoxic action mediated by IP-10. A significant increase
in neuronal cell death was observed upon exposure to 0.5
AM of IP-10 (P b 0.001), which was blocked by an
antibody directed against human CXCR3 (Fig. 4C), while
at the same concentration, IP-10 is not toxic to astrocytic
cells (Fig. 4C). Similarly, at concentrations lower than 0.5
AM, IP-10 showed nonsignificant neurotoxicity. Moreover,
neutralizing antibodies directed against other chemokine
receptors such as CXCR4 did not block the neurotoxic
actions of IP-10 (data not shown). Additionally, the
neurotoxic effects of conditioned media derived from
SINrep5-Nef YU-2-infected astrocytes were blocked using
the anti-CXCR3 antibody (Fig. 4D), suggesting IP-10
induced by the expression of Nef YU-2 in astrocytes was
acting as a neurotoxin in this system.
To explore the role of IP-10 induction in vivo by HIV-1
Nef further, brain sections of HIV/AIDS patients were
examined by immunocytochemical analyses (Fig. 5). IP-10
immunoreactivity was present in HIV-infected cases in cells
with astrocyte morphology (Fig. 5A), but was minimally
present in brain sections from controls (Fig. 5B). Astrocyte
expression of IP-10 was confirmed by colocalization of IP-
10 and glial fibrillary acidic protein (GFAP) immunoreac-
tivity (Fig. 5C). By examining the level of IP-10 mRNA
expression in brain (Fig. 5D), we found a significant
increase in IP-10 mRNA expression (P b 0.05) in patients
with HAD compared to HIV/AIDS patients without
dementia, while the level of Nef encoding transcripts (Fig.
5E) did not differ between groups. These latter findings
imply that IP-10 levels are increased in brain among HAD
patients but IP-10 expression was not related to an overall
increased Nef transcript abundance. As Nef sequence
variation influenced IP-10 expression in vitro, we next
examined Nef diversity in brain- and blood-derived
sequences.
Phylogenetic and protein structural analysis
We have previously found differences in viral molecular
heterogeneity and selection pressures acting on the HIV-1
Fig. 4. Analysis of pro-inflammatory gene expression in astrocytes infected with SINrep-Nef NL4-3, -Nef YU-2, -EGFP, or uninfected (mock) astrocytes using
real-time RT-PCR (A). Both Nef NL4-3 and YU-2 induced MCP-1 gene expression, while only IL-1h and IP-10 expressions were induced by Nef YU-2. The
induction of IP-10 gene expression by Nef YU-2 was the most pronounced with low expression induced by Nef NL4-3 and minimal expression in EGFP or
expressing uninfected astrocytes. (B) IP-10 protein immunoreactivity was detectable in SINrep5-Nef YU-2-infected cultures, but was absent in SINrep5-EGFP-
and mock-infected cultures. IP-10 immunoreactivity colocalized in cells that were immunopositive for Nef (insert). (C) Incubating neuronal (LAN-2) and
astrocytic (U373) cells with recombinant human IP-10 resulted in an increase in neuronal death at a concentration of 0.5 AM that could be blocked with a
neutralizing antibody directed against human CXCR3. Astrocyte survival was not affected by IP-10. (D) The neurotoxicity of conditioned media derived from
SINrep5-Nef YU-2-infected astrocytes was blocked by preincubating the neurons with the antihuman CXCR3 antibody, suggesting IP-10 induced upon Nef
expression in astrocytes acts as a neurotoxin (*P b 0.05, ***P b 0.001, Dunn’s multiple comparison test) (cell death untreated cells, 1.9 F 0.9%).
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HIV/AIDS patients with and without dementia (Bratanich
et al., 1998; Power et al., 1994, 1998b; van Marle et al.,
2002). To determine if the HIV-1 nef gene exhibited
similar differences in terms of selection pressures amongdifferent tissue compartments and patients groups, the
extent of viral molecular diversity in this region was
examined by comparing the nef sequences found in
peripheral blood lymphocyte (PBL) and brain from ND
and HAD patients. Analysis of the mean total (d),
Fig. 5. Expression of IP-10 in brains of HIV/AIDS patients. IP-10 immunoreactivity was detected in cells with astrocyte morphology in brains from AIDS
patients (A) but not in control brains (B). Double label immunohistochemical analysis showed colocalization of IP-10 immunoreactivity (brown) with
immunoreactivity for the astrocyte marker GFAP (blue) (C). Real-time RT-PCR analysis for IP-10 mRNA levels revealed a significant increase in IP-10 mRNA
levels (D) in brains of patients with HAD (n) compared to ND patients (E), while no differences were observed in levels of Nef mRNA in brain for both
groups (E) (the median for each group is represented by horizontal bar, *P b 0.05, Mann–Whitney test).
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distances (Nei and Gojobori, 1986) for the Nef sequences
within each group and tissue compartment indicated a
lower nonsynonymous distance for the sequences derived
from the brain of patients with HAD (P b 0.001)
compared to brain-derived sequences of ND patients as
well as the blood-derived sequences for both ND and
HAD patients (Fig. 6A). In addition, analysis of dN/dS
revealed significant differences in selection pressure
between sequences from ND and HAD patients in both
blood and brain (blood P b 0.01, brain P b 0.05) (Fig.
6B). The consensus nucleotide sequences for each patient
comprising the entire Nef encoding region derived from
blood or brain revealed no clustering of sequences by
neurological diagnosis nor tissue compartment (data not
shown). In addition, no obvious signature sequences or
alterations in amino acid residues critical for Nef function
(Doms and Trono, 2000) were observed based on align-
ment of the Nef amino acid sequences. These results
indicated that the Nef protein is more conserved in the
brain among HIV/AIDS patients with HAD, which may be
a consequence of differing selection pressures acting on
Nef.
The difference in selection pressure and viral diversity
suggested by phylogenetic analyses prompted us to examine
the possibility of viral evolution toward a specific protein
structure. A subset of the inferred Nef protein sequences
derived from brain (HAD, n = 5; ND, n = 5) and blood(HAD, n = 4; ND, n = 4) was subjected to a protein
structure analysis using the published crystal structures as
reference (Geyer et al., 1999; Grzesiek et al., 1997), while
variations in distances between specific structural landmarks
within the Nef protein were observed among both the brain
and blood-derived Nef proteins from the HAD and ND
patient groups, only the distance between the two a helices
(distance c) differed among the HAD and ND patients in
blood (P b 0.01) (Fig. 7D). Nonetheless, differences in
overall thermodynamic stability were observed among the
different patient groups and tissue compartments (P b
0.001) (Fig. 7D). Additionally, the HAD patients exhibited a
lower mean overall energy for their Nef protein compared to
blood-derived Nef proteins of ND patients. The energies for
the brain-derived Nef proteins for both ND and HAD
patients were significantly lower than for the blood-derived
Nef proteins from ND patients (P b 0.001). These results
indicate that the structure of the Nef proteins found in the
brain and in the blood of HAD patients is energetically more
favorable (i.e., stable), which may be a prerequisite for
infection of the brain.
Sequence diversity in the Nef protein results in differential
IP-10 induction
Given the differences in IP-10 induction by the different
prototypic Nef proteins, we examined the relationship
between Nef sequence diversity and IP-10 gene regulation
Fig. 6. Phylogenetic and protein structural analysis of Nef sequences obtained from blood and brain from HIV/AIDS patients with (HAD) and without (ND)
dementia. Brain-derived nef sequences of HAD patients were more conserved as reflected by lower nonsynonymous (i.e., amino acid changing mutation)
distances (dN) (A), with a increasing tendency to more negative or purifying selection (dN/dS b 1) in patients with HAD in both blood and brain (B). Protein
structure analysis using molecular distance measurements between structural landmarks (C) indicated limited variations apart from the distance between the
second and third a-helix (distance c), which was longer for protein structures obtained for Nef protein sequences found in blood of HAD patients (D).
However, the overall folding energies obtained for the Nef proteins found in blood of HAD patient was lower (i.e., more energetically favorable) than those
obtained for ND patients and comparable to the overall folding energies found in brain for both HAD and ND patients (D), suggesting viral evolution toward a
more energetically favorable conformation (*P b 0.05, **P b 0.01, ***P b 0.001, Dunn’s multiple comparison test).
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patients. To assess the extent to which the Nef proteins
cloned directly from brain are able to induce IP-10, PCR
fragments amplified from brain of two representative
patients containing the entire Nef ORF were cloned into
the pSINrep5 vector (ND, clone number 12C2 4 and HAD,
clone number 18C5). Recombinant Sindbis viruses encod-
ing for brain-derived Nef from ND or HAD patients were
constructed and Nef protein expression was confirmed
following infection of BHK cells, as described above (data
not shown). Astrocytic cells were infected with identical
multiplicities of infection (MOIs) for each brain-derived
Nef expressing recombinant virus, together with SINrep5-
Nef YU-2, SINrep5-EGFP, and mock-infected cells servingas controls. All Nef expressing recombinant viruses
induced MCP-1 gene expression relative to the EGFP
expressing virus and mock-infected cells (P b 0.05) (Fig.
7A) similar to our in vitro data. Although the HAD-Nef
virus did not induce IL-1h, the ND-Nef virus activated IL-
1h gene expression when compared to SINrep5-EGFP or
mock-infected astrocytes to levels higher than Nef YU-2
(P b 0.01) (Fig. 7B). Both brain-derived Nef proteins
induced IP-10 in astrocytes at a higher level than Nef YU-
2 (Fig. 7C), but the level of IP-10 expression was the
highest for the Nef protein derived from the patient with
HAD (P b 0.05). These results indicate that induction of
IP-10 expression and other pro-inflammatory genes is
dependent on the individual sequence of the Nef protein,
Fig. 7. Analysis of pro-inflammatory gene expression in brain-derived Nef
proteins in astrocytic cells using real-time RT-PCR. (A) Both brain-derived
Nef proteins 18C5 (HAD) and 12C2 4 (ND) induced MCP-1 gene
expression to a similar extent as Nef YU-2 compared to EGFP or uninfected
controls (mock). (B) Both Nef YU-2 and 12C2 4 (ND), but not Nef 18C5
(HAD), induced IL-1h when compared to controls. (C) Nef 18C5 (HAD)
and 12C2 4 (ND) induced the expression of IP-10, although induction of
IP-10 expression by the Nef protein 18C5 (HAD) was higher compared to
Nef YU-2 and 12C2 4 (ND) (*P b 0.05, **P b 0.01, Dunn’s multiple
comparison test).
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injury and death.Discussion
In the current study, intracellular HIV-1 Nef protein
expression caused astrocyte death and also induced the
release of neuronal cytotoxin(s). In vivo expression of the Nef
protein resulted in an inflammatory response and neuronal
loss accompanied by neurobehavioral abnormalities. Astro-
cytes expressing Nef exhibited high levels of IP-10 mRNA
together with soluble IP-10 causing neuronal death through
its cognate receptor CXCR3. IP-10 induction in astrocytes
was also dependent on the sequence of the Nef protein, which
complemented the findings of brain-derived Nef sequence
diversity among patients. These findings demonstrate that the
HIV-1 Nef protein exhibits molecular heterogeneity, which
can contribute to neuropathogenesis through the induction of
the chemokine IP-10, which is cytotoxic to neurons.
Cell death in astrocytes resulting from intracellular
expression of a prototypic Nef protein has been reported
(He et al., 1997). However, using the present alphavirus
expression system, we were able to study both primary
astrocytes and astrocytic cell lines, showing cell death upon
intracellular expression of the Nef protein but apoptosis was
not a consistent feature, based on p53 upregulation and
caspase-3 activation (data not shown). We also observed
variability in the extent of cell death, which was dependent
on the individual sequence of the Nef protein; indeed, this
might explain the differences in the induction and mecha-
nism of astrocyte death by different researchers (He et al.,
1997; Kohleisen et al., 1999; Robichaud and Poulin, 2000).
The induction of apoptosis by Nef in astrocytes has been
attributed to the overexpression of the proto-oncogene c-kit
(He et al., 1997), but Nef also affects multiple other
molecules in different cell death pathways, including p53
and Bad (Fackler and Baur, 2002). The exact mechanism by
which astrocytes undergo cell death upon intracellular
expression of Nef is currently under investigation in our
laboratory, although p53 does not appear to be involved
(data not shown). Nonetheless, astrocyte death is an
important aspect of HIV-1-induced neurological disease
(Shi et al., 1996; Wesselingh and Thompson, 2001), given
that astrocytes are sources of several trophic factors
ensuring neuronal survival.
The role of sequence variability within the nef gene as an
important pathogenic determinant is illustrated in our study
by differential induction of pro-inflammatory gene expres-
sion (IL-1h, MCP-1, and IP-10) by prototypic blood-derived
(NL4-3) and brain-derived (YU-2) Nef proteins. Moreover,
these findings were recapitulated in our observations of two
brain-derived Nef proteins from patients with and without
dementia in astrocytes. The induction of gene expression of
the chemoattractant molecules MCP-1 and IP-10 corresponds
with the ability of the Nef protein to potentiate inflammatory
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et al., 2001; Kay et al., 2002; Koedel et al., 1999; Poudrier et
al., 2001; Sporer et al., 2000); although herein IP-10
activation was dependent on Nef sequence heterogeneity. In
several viral infections, including infections of the nervous
system, induction of IP-10 is involved in recruitment of
immune cells to the site of infection (reviewed in Asensio and
Campbell, 2001). In the context of HIV-1, IP-10 is increased
in the cerebrospinal fluid (CSF) of patients with neurological
disease (Kolb et al., 1999) and in the brains of macaques
infected with simian immunodeficiency virus (SIV) or the
SIV/HIV chimeric virus (SHIV) (Sasseville et al., 1996; Sui
et al., 2003; Westmoreland et al., 1998). The IP-10
immunoreactivity observed in astrocytes of HIV/AIDS
patients’ brains, as well as the elevated IP-10 gene expression
in brains of HIV/AIDS patients with HAD compared to non-
demented patients, complements observations that the HIV-1
envelope and exogenous Tat proteins induce IP-10 expres-
sion in astrocytes (Asensio et al., 2001; Kutsch et al., 2000).
Moreover, our results extend these studies by showing that
the intracellular expression of the Nef protein also induced
IP-10 expression in primary astrocytes, which was dependent
on the Nef protein sequence. Infection of astrocytes by HIV-1
is poorly understood, and it needs to be noted that expression
of Nef in astrocytes has primarily been observed in brain of
pediatric neuroAIDS cases (Saito et al., 1994; Tornatore et al.,
1994a), but HIV-1 provirus has been detected in astrocytes of
adult brains in several studies, while expression of the Nef
protein in astrocytes in adult brain has also been reported,
although less consistent (Ranki et al., 1995; Takahashi et al.,
1996; Trillo-Pazos et al., 2003).
We also demonstrated that the IP-10 produced by
astrocytes upon Nef expression is cytotoxic to neurons
through its interaction with its cognate receptor CXCR3. In
Alzheimer’s disease, an upregulation of IP-10 expression
in astrocytes is also observed and the cell signaling events
initiated by IP-10 through CXCR3 on neurons have been
suggested to play a role in neuronal dysfunction (Xia et al.,
2000). Of interest, IP-10 concentrations in CSF of HIV/
AIDS patients (Kolb et al., 1999) were in the same order
of magnitude to the neurotoxic IP-10 concentrations used
in the current study. Recently, we have reported the
neurotoxic action of another chemokine, stromal cell-
derived factor 1 (SDF-1) (Zhang et al., 2003), due to
cleavage of SDF-1 by MMP-2. A similar mechanism may
underlie the neurotoxic action of IP-10 in vivo by altering
interaction with CXCR3 and synergistic effects through
interaction of either cleaved or uncleaved molecules with
alternative receptors, as has been observed in the cleaved
form of SDF-1 (Zhang et al., 2003). To what extent
neurotoxicity of the IP-10 mouse homologue mCRG-2
plays a role in the brain pathology observed in SINrep5-
Nef YU-2-implanted mice remains to be determined.
Immunocytochemical analysis for mCRG-2 expression
was unremarkable (data not shown), and because human
IP-10 and mCRG-2 differ by approximately 30% at theamino acid level (Vanguri and Farber, 1990), their mode of
action concerning neuronal death may differ. Finally, it is
noteworthy to mention recent findings by Lane et al.
(2003) indicating that IP-10 enhances HIV-1 replication, as
this may be another mechanism by which IP-10 can
contribute to HIV-1 neuropathogenesis.
Although, we examined a limited number of Nef proteins
in terms of inflammatory gene expression induction, clear
differences in their ability to induce MCP-1, IL-1h, and IP-
10 were observed. The brain-derived Nef protein from the
patient with HAD was the most potent inducer of IP-10
expression, but more brain-derived Nef proteins will need to
be assessed to determine if this is a common property of all
HAD-associated Nef proteins. Nonetheless, they underscore
the importance of viral molecular heterogeneity as a
possible pathogenic determinant.
We previously reported that viral evolution in HAD and
ND patients occurred in both blood and brain likely due to
differential selection pressures acting on the HIV-1
envelope region (van Marle et al., 2002). In the current
study, we also observed differences between HAD and ND
in blood and brain in selection pressures acting on Nef. In
contrast to the envelope region, which is subject to both
cellular and humoral immune pressure, Nef is primarily a
target for the cellular immune response (Addo et al., 2002;
Altfeld et al., 2001; Letvin and Walker, 2003; Walker and
Goulder, 2000), which is reflected in the difference in
magnitude and primarily negative or purifying selection
pressure as suggested by the dN/dS Nef values (b1) when
compared to those reported for the envelope region, which
is subject to both positive (dN/dS N 1) and negative
selection pressures depending on the individual domain
(van Marle et al., 2002). The more conserved Nef protein
sequence in the brain of HAD patients may reflect the
purifying selection pressures acting on this region in both
blood and brain of this patient group. Moreover, the
energetically more favorable protein structure found in
blood of HAD patients, similar to those found in brain of
both ND and HAD patient, potentially reflects viral
evolution in the blood toward a more neurotropic Nef
sequence. Taken together, these observations agree with
our previous findings suggesting viral evolution toward
increased neurovirulence, which may represent an impor-
tant aspect of HIV-1 neuropathogenesis (van Marle et al.,
2002). Differential induction of neuroinflammation as a
result of sequence diversity in viral genes may contribute
to diverse nature of neurological disease development in
HIV/AIDS patients, as previously reported for neurotropic
murine retroviruses (Peterson et al., 2001; Poulsen et al.,
1998) and neurotropic animal lentiviruses (Johnston et al.,
2002; Power et al., 1998a; Zink et al., 1997). Indeed, the
current observations also have important implications for
developing antiviral therapies or therapeutic vaccination
strategies that impact extensively on viral evolution within
the host and potentially increase the chance of generating
neurovirulent HIV-1 strains during infection.
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Construction of SINrep5-EGFP and SINrep5-Nef vectors
The SINrep5 vector system and the construction of the
SINrep5 vector expressing enhanced green fluorescent
protein (EGFP) (SINrep5-EGFP) used in this study have
been described previously (van Marle et al., 2003).
Constructs pSINrep5-Nef YU-2 and pSINrep5-Nef NL4-3
were obtained as follows. Using a molecular clone of brain-
derived HIV-1 strain YU-2 (Li et al., 1991) and blood-
derived clone NL4-3 (Adachi et al., 1986) as template, the
nef open reading frames (ORFs) were amplified by PCR
using primers NEF8748F (5V-GAA GAA TAA GAC AGG
GCT -3V) and NEF9425R (5V-AGT CCC CAG CGG AAA
GTC CC-3V), pfu polymerase, and an annealing temperature
of 50 8C. The resulting PCR fragments were isolated from
gel, the incomplete fragment ends filled in with Klenow,
phosphorylated using T4 polynucleotide kinase, and cloned
into the StuI site of the multiple cloning site of pSINrep5. In
a similar fashion, pSINrep5-Nef expression vectors were
constructed using the nef ORF containing PCR fragments
amplified from the brain-derived cDNA of HIV-1-infected
patients with and without dementia. Correct insertion of the
inserts was determined by restriction enzyme digest analysis
and subsequent sequencing of the insert to ensure no
mutations had been introduced during amplification. All
restriction and other enzymes were obtained from New
England Biolabs (Mississauga, ON) or Invitrogen (Burling-
ton, ON) and used according to their specifications.
Production of SINrep5-EGFP and SINrep5-Nef virus stocks
The pSINrep5-EGFP and the helper virus construct pDH-
BB (Bredenbeek et al., 1993) were linearized with XhoI and
the pSINrep5-Nef constructs were linearized with NotI. The
linearized plasmids were used as templates for the gen-
eration of capped RNA transcripts by in vitro run-off
transcription using the SP6 mMESSAGE mMACHINE kit
(Ambion Inc, Austin, TX). Ten micrograms of DH-BB
RNA transcript and 10 Ag SINrep5-EGFP or SINrep5-Nef
vector RNA transcript were transfected to 3–5  106 BHK-
21 cells/ml in PBS by electroporation according to a
previously published protocol (Bredenbeek et al., 1993) in
which the cells were subjected to two pulses at 800 V, 50 AF,
and l V using a Gene Pulser II (Bio-Rad Laboratories
Canada Ltd., Missisauga, ON). Cells were plated in culture
media and incubated at 37 8C/5% CO2. The media
containing recombinant SIN were harvested 20–24 h after
transfection. For SINrep5-EGFP virus, the titer was
determined by counting the number of EGFP-positive
BHK cells using fluorescent microscopy 24 h postinfection.
To determine the titer of SINrep5-Nef viruses, BHK cells
were subjected to immunofluorescent analyses using a
monoclonal or polyclonal antibody directed against the
HIV-1 Nef protein (NIH AIDS research and ReferenceReagent Program, Cat nr. #1539 and #2949, respectively)
and the Nef-immunopositive cells were counted. On
average, 106 to 107 infectious virus particles/ml were
obtained for SINrep5-EGFP and 106 particles/ml for the
SINrep5-Nef virus stocks.
Stereotactic implantation of SINrep5-Nef YU-2 in the mouse
striatum
The right striatum of 3-week-old male SCID/NOD mice
was stereotactically implanted with SINrep5-Nef YU-2
(4.6  106 particles/ml) (n = 6) in a volume of 2 Al over 5
min in accordance with CACCA guidelines. As controls,
mice were injected with the same volume of SINrep5-EGFP
(4.6  106 particles/ml) (n = 6) or BHK-conditioned media
(CM) (n = 6). The coordinates for the implantation were 3
mm posterior, 2.5 mm lateral, 3 mm deep relative to the
bregma. Rotary behavior of the implanted animals was
analyzed at 3, 7, and 14 days after implantation, following
intraperitoneal injection of 1 mg/kg of amphetamine
(Johnston et al., 2001, 2002; Ungerstedt and Arbuthnott,
1970). Animals were sacrificed at day 14 by intracardial
perfusion with saline, followed by PBS/4% paraformalde-
hyde. The brain was removed and post-fixed in PBS/4%
paraformaldehyde embedded in paraffin from which 10-Am
sections were prepared.
Immunofluorescent analysis of cells and tissue sections
Tissue sections were deparaffinized and rehydrated and
subjected to immunofluorescence analysis using antibodies
directed against the astrocyte marker glial fibrillary acidic
protein (GFAP, Dako, Glostrup, Denmark), the activated
microglial cell marker ionized calcium binding adaptor
molecule 1 (Iba-1) (Imai et al., 1996; Ito et al., 1998), and
neuronal nuclei (NeuN) (Chemicon Int., Temecula, CA)
using previously described procedures (Power et al., 1993),
and the appropriate Cy3-conjugated secondary antibodies
(Molecular Probes, Eugene, OR). All tissue slices and cells
were analyzed by fluorescent microscopy using a standard
fluorescent microscope setup (Axioskop 2, Carl Zeiss
Canada Ltd., Toronto, ON). In addition, paraffin-embedded
human brain sections from control patients or patients with
HIV-1 encephalitis were subjected to immunohistochemical
analysis using previously described protocols (Power et al.,
1993), including antibodies directed against human IP-10
(R&D Systems, Cedarlane Laboratories Ltd., Hornby, ON)
and a monoclonal antibody directed against astrocyte
marker GFAP (Dako).
Cells mock infected or infected with SINrep5-EGFP or
SINrep5-Nef viruses were fixed in 4% paraformaldehyde
for 20 min and washed with PBS and subjected to
immunofluorescent analysis using antibodies directed
against IP-10 (R&D Systems, Cedarlane Laboratories
Ltd.), Nef (NIH AIDS research and Reference Reagent
Program, Cat nr. #1539 and #2949), and the astrocyte
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secondary antibodies (Molecular Probes).
Analysis of cytotoxicity of SINrep5-Nef vectors in vitro
LAN-2 (human cholinergic neurons) and U373 cells
(human transformed astrocytes) were infected for 24 and
48 h with SINrep5-Nef viruses using a multiplicity of
infection (MOI) of 1 and 5, and using SINrep5-EGFP at
similar MOI as control. As additional control (mock), equal
volumes of conditioned medium (CM), obtained from
mock-transfected BHK cells, were incubated with the
different cell lines. After 24 and 48 h, the percentage of
cell death was assessed by trypan blue exclusion and
compared to the SINrep5-EGFP and mock-infected con-
trols. The cytotoxicity was tested in triplicate in two
separate experiments for each cell line and each recombi-
nant virus. In all cytotoxicity experiments, cell death was
expressed as relative fold change or increase (RFC) of cell
death in control (uninfected) cells.
The indirect cytotoxic effects of the Nef proteins was
tested by infecting human MDM, as well as human primary
astrocytes, with the SINrep5-EGFP and SINrep5-Nef
viruses for 4 h at 37 8C/5% CO2. All MDM and astrocyte
infections were performed in duplicate. The inoculum was
replaced with AIM-V media (Invitrogen) and cells were
incubated for 20 h at 37 8C/5% CO2. In addition, cell death
in human MDM and primary astrocytes was measured by
trypan blue exclusion 24 h after initial infection by SINrep5-
EGFP, SINrep5-Nef, and CM. Subsequently, the condi-
tioned media of the MDM and primary astrocytes were
tested for neurotoxicity by incubating the human LAN-2
cell line for 24 and 48 h with that conditioned AIM-V
media, and determining cell death by trypan blue exclusion.
As control, conditioned media of MDM and primary
astrocytes incubated with CM from mock-transfected
BHK cells were used. The cytotoxicity of conditioned
media derived from the MDM and primary astrocytes was
tested in triplicate in two separate experiments. To assess the
role of IP-10 and its cognate receptor CXCR3 in neuronal
death, the cytotoxicity to neurons of conditioned media
derived from primary astrocytes was also determined in the
presence of an antibody directed against human CXCR3
(R&D Systems, Cedarlane Laboratories Ltd.) after preincu-
bation for 1 h at 37 8C/5% CO2.
Western blot analysis
SINrep5-Nef, SINrep5-EGFP, or mock-infected BHK-21
cells or human fetal astrocytes were lysed in 1% SDS, 24 or
48 h after infection. Total protein concentration of these
lysates was determined using the Bio-Rad protein assay
(Bio-Rad Laboratories Canada Ltd.), and the protein lysates
were subsequently subjected to standard Western blot
analysis. Briefly, 50 Ag of protein from cells was separated
on a 15% SDS/Polyacrylamide gel, transferred to nitro-cellulose, blocked for 6 h at room temperature in 10% skim
milk powder in TBS/0.1% Tween 20 (TBST), 15 h at 4 8C in
5% milk/TBST with antibodies directed against the Nef
protein (NIH#1539 or NIH#2949 1:1000 dilution each), and
after four washes in TBST the blots were incubated for 4 h at
room temperature with the appropriate horseradish perox-
idase-conjugated secondary antibodies (Sigma-Aldrich Can-
ada Ltd., Oakville, ON) in 5% milk/TBST, washed four
times in TBST and two times in TBST, and subsequently
visualized using the Roche enhanced chemiluminescence
(ECL) kit (Roche Diagnostics Canada, Laval QC).
Real-time RT-PCR analysis
Cellular RNA was extracted from SINrep5-Nef YU-2,
SINrep5-EGFP, and mock-infected astrocytes 24 h post-
infection using Trizol reagent (Invitrogen), and subse-
quently cDNA synthesis was performed (Boven et al.,
2003). The cDNA was diluted 1/1 with water, and 5 Al was
used per PCR reaction. Real-time quantitative PCR was
performed using the iCycler IQ system (Bio-Rad), with each
25-Al reaction containing 5 Al of cDNA, 11.5 Al of
Supermix (Bio-Rad), 6.5 Al of SYBR-Green (1/50000
dilution; Bio-Rad), 1 Al of fluorescein (1/10000; Bio-
Rad), and 1 Al of primer mix. The amplification protocol
consisted of an initial denaturation step of 3 min at 95 8C,
followed by 45 cycles of 95 8C for 30 s, 30 s at the
annealing temperature (Tm) of the primers, and 72 8C for
30 s. The primers used: IP-10 Forward 5V-CCT TCC TGT
ATG TGT TTG GA-3V, Reverse 5V-CCT GCT TCA AAT
ATT TCC CT-3V (Tm = 55 8C, 1.25 AM each primer), MCP-
1 Forward 5V-GCG AGC TAT AGA AGA ATC ACC-3V,
Reverse 5V-ATA AAA CAG GGT GTC TGG GG-3V (Tm =
60 8C, 2.5 AM each primer), IL-1h Forward 5V-CCA AAG
AAG AAG ATG GAA AAG CG-3V, Reverse 5V-GGT GCT
GAT GTA CCA GTT GGG-3V (Tm = 59 8C, 2.5 AM each
primer), Nef Forward (NEF8748F) 5V-GAA GAA TAA
GAC AGG GCT-3V Reverse (NEF8879R) 5V-TCC CAC
CCC ATC TGC TGC TGG-3V (Tm = 50 8C, 2.5 AM each
primer), GAPDH Forward 5V-AGC CTT CTC CAT GGT
GGT GAA GAC-3V, Reverse 5V-CGG AGT CAA CGG ATT
TGG TCC-3V (Tm = 55–60 8C, 2.5 AM each primer).
Following a final elongation step of 72 8C for 1 min, the
amplicons were subjected to a melt curve analysis to ensure
proper amplification, in which the temperature was raised
from 65 to 99 8C in 1 8C increments, and data were acquired
for 8 s at each temperature increment. The mRNA levels
were normalized against GAPDH and expressed as relative
fold change over RNA levels in mock-infected cells. All
real-time RT-PCR quantifications were performed in dupli-
cate and repeated with cDNAs from two or more different
independent infection experiments. To determine IP-10 and
MCP-1 mRNA levels in brain, cDNAs synthesized using
RNA isolated from brain of patients with and without
dementia (Wesselingh et al., 1993) were used and subjected
to the same real-time RT-PCR analysis again normalizing
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were expressed as relative fold change to RNA levels in
brain of ND patients.
Clinical blood and brain samples
Genomic DNA was obtained from peripheral blood
lymphocytes (PBL) with consent from patients with and
without HIV-1 associated dementia, from the St Michael’s
Hospital HIV Neuropsychology Laboratory (Toronto, ON),
and the Southern Alberta Clinic (Calgary, AB) (van Marle et
al., 2002). The samples utilized were obtained from patients
diagnosed as non-demented (ND, n = 10) and HIV-
associated dementia (HAD, n = 10) using established
criteria and neurological impairment was assessed by
standard neuropsychological testing, as described previ-
ously (Grant et al., 1995; Heaton et al., 1995; Janssen, 1991;
Kim et al., 2001; The DANA Consortium, 1996). In
addition, cDNA from autopsied brain tissue was obtained
from a different cohort of patients consisting of five HAD
and five ND patients described previously (Power et al.,
1994).
PCR and sequencing
The HIV-1 nef gene containing the entire Nef open
reading frame (ORF) region was amplified from the
integrated proviral DNA using 0.2–1 Ag of chromosomal
DNA isolated from PBL or from a 1:10 dilution of brain-
derived cDNA. The nested PCR protocol, which after an
initial denaturation step of 5 min at 94 8C, consisted of 40
cycles 1 min at 95 8C, 1 min at 50 8C, 2 min at 72 8C,
followed by a final extension step of 10 min at 72 8C, for
both first and second round PCR. The primers used for the
first round PCR were NEF8678F (5V-GTA GCT GAG GGG
ACA GAT AG-3V) and NEF9540R (5V-AGG CTC AGA
TCT GGT GTA AC-3V), and for the second round
NEF8748F (5V-GAA GAA TAA GAC AGG GCT-3V) and
NEF9425R (5V-AGT CCC CAG CGG AAA GTC CC-3V)
were used. PCR fragments were isolated from gel using the
QiaQuick gel extraction kit (Qiagen, Missasagua, ON) and
sequenced directly in both directions using the NEF8748F
and NEF9450R primers. DNA sequences were determined
by automated sequencing on an ABI 370 sequencer
(Applied Biosystems, Streetsville, ON) using the manufac-
turer’s protocols and reagents. As control, the cloned Nef
region of HIV NL4-3 was subjected to the same nested PCR
protocol as the patient DNA samples and subsequently
sequenced (data not shown). This analysis was repeated
several times and did not reveal any differences in the
sequence of the obtained PCR products to the original
sequence, which would exclude mutations introduced by the
PCR as an explanation for any observed difference in
sequences. The sequences obtained from cloned and PCR
fragments were aligned using DNAStar version 3.82
(DNAStar Inc. Madison, WI) and the consensus sequenceobtained for each patient was used for subsequent phylo-
genetic and structural analyses. All sequences have been
submitted to GenBank (accession numbers AY701253–
AY701286).
Sequence and phylogenetic analysis
The brain- and blood-derived nef sequences were
analyzed using the MEGA version 2.0 software package
(Kumar et al., 2001). Mean total (d), nonsynonymous (dN,
i.e., codon changing substitutions), and synonymous (dS,
i.e., non-codon changing substitutions) distances (Nei and
Gojobori, 1986) for the nucleic acid sequences covering the
entire Nef ORF were calculated for each patient group by
pair-wise comparison and pair-wise gap stripping of each
sequence with the other sequences within the same group.
Similarly, the mean dN/dS ratio within each group (ND and
HAD) was also calculated. Any bias toward nonsynon-
ymous or synonymous substitutions results in a different
dN/dS ratio that gives information about the selection
pressures acting on a given replicating sequence (Over-
baugh and Bangham, 2001). The MEGA software was also
used to construct neighbor-joining trees using the Jukes–
Cantor correction with 1000 replicates for the bootstrap
analysis.
Protein structural analysis
The Nef protein sequences were subjected to a protein
structure analysis using Spartan ’02 R (Wavefunction,
Irvine, CA) using the published Nef protein structure as
reference (Geyer et al., 1999; Grzesiek et al., 1997).
Molecular structures were minimized using the desktop
minimization function, followed by a SYBYL molecular
mechanics minimization. The energy and various distances
between structural landmarks of the output molecule were
recorded and evaluated for statistical differences between
averaged demented (HAD) and non-demented (ND)
patients. The following distances were measured (all amino
acid positions based on Nef YU-2): distance a, N-terminus
to C-terminus; distance b, N-terminus to start second a-
helix (position 93–103); distance c, end second a-helix
(position 93–103) to start third a-helix (position 115–127);
distance d, end second a-helix (position 93–103) to end
third a-helix (position 115–127); distance e, position 109
(between second and third a-helix) to position 141 (between
third a-helix and start h-sheet (position 152). Distances
were measured using the distance function of Spartan ’02.
For the blood-derived nef sequences, the protein loop
stretching from the E to D amino acid residues (positions
163 to 183 in Nef YU-2) was also analyzed, because this
region has been reported to interact with many cellular
factors, which may be relevant to pathogenesis (reviewed in
Doms and Trono, 2000). Constraints were introduced into
the loop, separated from the remainder of the protein, to
ensure that it remained in the loop shape.
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All statistical analyses were performed using Graphpad
InStat Version 3.01. (GraphPad Software, San Diego, CA)
and P values of less than 0.05 were considered significant.Acknowledgments
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